Exclusive Distribution Agreement Signed Between Hempacco and CBDAY in India and Thailand

Business by 2FIRSTS.ai

Dec.08.2023

Exclusive Distribution Agreement Signed Between Hempacco and CBDAY in India and Thailand

Hempacco Co, Inc. (HPCO) has signed an exclusive distribution agreement with CBDAY Global Private Limited to sell cannabis products in India and Thailand.

According to a report by Benzinga on December 6th, the cannabis tobacco company Hempacco Co, Inc. (code: HPCO) has announced that it has signed an exclusive distribution agreement with CBDAY Global Private Limited (a company that imports, exports, distributes, and sells hemp-based products in India and Asia).

According to the agreement, CBDAY will have exclusive sales rights for Hempacco's cannabis and CBD products in India and Thailand. The initial offerings will include Cheech & Chong and Rick Ross' marijuana products, which will be available for purchase on CBDAY's flagship website. These premium cannabis products will be distributed throughout the Asia region via CBDAY's extensive online and offline sales channels. This expansion reflects their commitment to providing high-quality hemp and CBD products to consumers worldwide.

The Indian market holds immense potential for cannabis-based products due to the country's long-standing use of the hemp plant for various purposes. In certain regions of India, particularly the state of Uttar Pradesh, some tribal communities may engage in the use of marijuana, and related laws might have a degree of leniency towards them.

References:

[1] Cheech & Chong, Rick Ross, Hemp Products Hit Shelves In India And Thailand Via Hempacco-CBDAY Partnership

Also Read:

[1] Controversial Revisions Proposed for Ohio's Marijuana Legalization Initiative

[2] Argentine Police Seize Marijuana Lab and Derivative Factory

[3] Ohio City Council Passes 6-Month Ban on E-Cigarette and Marijuana Businesses

#Asia #India #Market #CBD #Products #Thailand

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

ceshi1111

Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st

Oct.21

Philippines’ DTI Proposes Mandatory Advertising Permits for Vape Products

The Philippine Department of Trade and Industry (DTI) has released a draft Department Administrative Order (DAO) seeking public feedback on a new permitting system for advertising and promoting vaporized nicotine and non-nicotine products.

Dec.08 by 2FIRSTS.ai

Illegal tobacco syndicate dominates Australia’s vape market through threats and extortion

Australia’s The Age has revealed that a local tobacco cartel is working with a crime syndicate to dominate the illicit vape trade. The Australian Border Force (ABF) intercepted 115,200 vapes worth A$4.5 million disguised as “furniture” at Sydney port. Authorities say over 12 million illegal vapes have been seized since 2024.

Nov.03

Irish Cabinet to Consider Bill Banning Sale of Single-Use Vapes

Ireland’s Minister for Health, Jennifer Carroll MacNeill, will seek Cabinet approval today for the publication of the Public Health (Single-Use Vapes) Bill 2025, which proposes banning the retail sale of single-use or disposable vapes six months after becoming law. The measure aims to address the growing use of disposable vapes, particularly among young people, and close regulatory gaps around emerging nicotine products such as pouches.